Pages that link to "Q52914148"

The following pages link to K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. (Q52914148):

Displaying 50 items.

• The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis (Q24650902) (← links)
• A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk (Q24655762) (← links)
• Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy (Q24809183) (← links)
• Can microRNAs improve the management of lung cancer patients? A clinician's perspective (Q26999304) (← links)
• Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy (Q27313799) (← links)
• CLEFMA-an anti-proliferative curcuminoid from structure-activity relationship studies on 3,5-bis(benzylidene)-4-piperidones (Q30496742) (← links)
• High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. (Q33267389) (← links)
• Tobacco-related diseases. Is there a role for antioxidant micronutrient supplementation? (Q33890743) (← links)
• Clinical relevance of KRAS in human cancers (Q33959887) (← links)
• Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation (Q34200895) (← links)
• Blocking oncogenic Ras signaling for cancer therapy (Q34311585) (← links)
• Prognostic molecular markers in non-small cell lung cancer (Q34447423) (← links)
• Identification of RASSF8 as a candidate lung tumor suppressor gene (Q34492221) (← links)
• The role of extracellular matrix in small-cell lung cancer (Q34571963) (← links)
• Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions (Q34623884) (← links)
• The curcuminoid CLEFMA selectively induces cell death in H441 lung adenocarcinoma cells via oxidative stress (Q35032472) (← links)
• Adjuvant therapy in completely resected non-small-cell lung cancer (Q35142848) (← links)
• RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally (Q35683647) (← links)
• Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer (Q36536565) (← links)
• Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors (Q36547786) (← links)
• Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. (Q36716682) (← links)
• The Ras/Raf/MAPK pathway (Q36780542) (← links)
• Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis (Q36915616) (← links)
• Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. (Q36917485) (← links)
• Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping (Q37141952) (← links)
• Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. (Q37226800) (← links)
• Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations (Q37382669) (← links)
• Parameters for individualizing systemic therapy in non-small cell lung cancer (Q37398845) (← links)
• Individualized therapy in non-small-cell lung cancer: future versus current clinical practice (Q37579648) (← links)
• Molecular predictive and prognostic markers in non-small-cell lung cancer. (Q37606747) (← links)
• Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer (Q37744346) (← links)
• Novel biomarkers of metastatic cancer (Q37772496) (← links)
• Predictive markers in the adjuvant therapy of non-small cell lung cancer (Q37925277) (← links)
• Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables (Q37929588) (← links)
• Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer (Q37996270) (← links)
• EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients? (Q38089244) (← links)
• Prognostic and predictive factors in resected non-small-cell lung cancer (Q38089884) (← links)
• New and potential clinical applications of KRAS as a cancer biomarker (Q38089885) (← links)
• Molecular targets in the treatment of non-small-cell lung cancer: is there hope on the horizon? (Q38267142) (← links)
• Regulatory single nucleotide polymorphisms at the beginning of intron 2 of the human KRAS gene. (Q38294882) (← links)
• MET inhibition in lung cancer (Q38390016) (← links)
• Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2. (Q38734002) (← links)
• Detection of EGFR and KRAS mutations in fine-needle aspirates stored on Whatman FTA cards: is this the tool for biobanking cytological samples in the molecular era? (Q39607021) (← links)
• KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma (Q40542208) (← links)
• Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis (Q40773360) (← links)
• Prevalence of K-RAS Codons 12 and 13 Mutations in Locally Advanced Head and Neck Squamous Cell Carcinoma and Impact on Clinical Outcomes (Q40811967) (← links)
• The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer (Q42274351) (← links)
• Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene (Q42661743) (← links)
• Identification of candidate genes for lung cancer somatic mutation test kits (Q42665905) (← links)
• A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens (Q42673662) (← links)